MAM
CPRX

Martingale Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Martingale Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-139,535
Closed -$3.45M – 840
2026
Q1 		$3.45M Buy
139,535
+19,852
+17% +$473K 0.09% 226
2025
Q4 		$2.79M Sell
119,683
-715
-0.6% -$15.9K 0.07% 249
2025
Q3 		$2.37M Buy
120,398
+8,058
+7% +$166K 0.06% 273
2025
Q2 		$2.44M Buy
112,340
+23
+0% +$543 0.06% 265
2025
Q1 		$2.72M Buy
112,317
+1,350
+1% +$30.4K 0.07% 228
2024
Q4 		$2.32M Buy
110,967
+23,890
+27% +$513K 0.06% 280
2024
Q3 		$1.73M Buy
+87,077
New +$1.61M 0.04% 347
2022
Q4 		– Sell
-56,476
Closed -$725K – 835
2022
Q3 		$725K Sell
56,476
-45,226
-44% -$536K 0.01% 534
2022
Q2 		$714K Buy
+101,702
New +$746K 0.01% 563

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Martingale Asset Management's CPRX Position: Q2 2026 in Review

Martingale Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 139,535 shares — an estimated $3.45M sold.

Martingale Asset Management first reported a position in CPRX in Q2 2022 and held it in 9 quarters. The position peaked at $3.45M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Martingale Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Martingale Asset Management sold 139,535 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.45M.
  • Martingale Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 9 quarters.
  • Martingale Asset Management's Catalyst Pharmaceutical position peaked at $3.45M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.